U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Cancer Institute (NCI) http://www.cancer.gov/ FOR IMMEDIATE RELEASE: Thursday, September 29, 2005 CONTACT: NCI Press Office, 301-496-6641, ncipressofficers@xxxxxxxxxxxx NCI AND 10 OTHER INSTITUTIONS LAUNCH OVARIAN CANCER CLINICAL TRIAL The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is leading a clinical trial designed to build a repository of blood samples in order to develop an accurate means of detecting ovarian cancer soon after the disease returns. Researchers will collect a series of blood samples from women with advanced-stage ovarian cancer who show no signs of cancer after completing their first program of chemotherapy for ovarian cancer. According to study lead Elise Kohn, M.D., Center for Cancer Research, NCI, "If we can harness all of the protein information in our patient's samples, we may have a strong lead on how to detect ovarian cancer at an early stage when it can be most effectively treated. CA-125 (a test for a protein that is detectable in 80 percent of advanced stage patients with epithelial ovarian cancer) is currently the only approved test to see if ovarian cancer has returned, but it is not able to reliably diagnose women who have no signs of ovarian cancer." The scientists' long-term goal is to make a test that can predict the presence of early stage ovarian cancer using new technology that examines blood proteins. Advanced-stage ovarian cancer has a high likelihood of returning within three years of initial treatment even when there are no signs of cancer being present. Current tests, such as CA-125 and transvaginal ultrasound, do not have good ability to predict whether cancer will return or not or for finding it in the first place. New biomarkers, such as those found in blood, are urgently needed. The trial will enroll 400 women over 24 months. Researchers are looking for women who have advanced-stage ovarian cancer, have completed their initial chemotherapy within 9 weeks of starting this trial, and show no evidence of cancer following completion of their first treatment program for which they received drugs such as carboplatin or cisplatin with paclitaxel, or docetaxel. The women will have a physical exam and routine laboratory tests performed every three months and a CT scan of the abdomen and pelvis (plus chest if indicated) every six months. Research samples will be frozen to create a repository for analysis of blood proteins. The study will also compare the blood protein test that is developed with CA-125 to see if it is better at predicting return of cancer than CA-125. Additional blood samples will be stored to create a repository so that other promising blood tests for ovarian cancer may be studied. "A pilot study launched in 2000 gave us a better understanding of the complexities of protein analysis and reinforced the importance of collecting and analyzing a large number of blood samples and their protein patterns. After carefully analyzing our processes and procedures during that pilot study, we now have the opportunity to incorporate those advances and to gather a larger patient pool, expand our partnerships, and make sure that we do not create false-positive results for our patients," said Kohn. The trial's leaders note that their goal is to create the best, most accurate, validated test so patients can have a high level of confidence when their results come back. Ovarian cancer accounts for approximately four percent of all women's cancers and is the fourth leading cause of cancer-related death among women in the United States, with close to 16,000 women expected to die of the disease in 2005. For more information or to enroll in the trial at NCI's Bethesda, Maryland location, please call 1-888-NCI-1937 (1-888-624-1937). Women who are not eligible for this trial but are interested in joining a different clinical trial are invited to contact NCI at 1-800-4-CANCER or go to www.cancer.gov/clinicaltrials. The first site opening for this trial is at NCI's clinical facility on the NIH campus in Bethesda, Maryland. Ten other sites will begin enrolling patients later in 2005 or in 2006. The other participating institutions include: -- Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Wash. -- Cedars Sinai Medical Center, Los Angeles, Calif. -- University of Alabama at Birmingham -- Duke University Medical Center, Durham, N.C. -- Fox Chase Cancer Center, Philadelphia, Pa. -- University of Texas MD Anderson Cancer Center, Houston, Texas -- Massachusetts General Hospital, Boston, Mass. -- Northwestern Memorial Hospital, Chicago, Ill. -- Evanston Northwestern University Hospital, Evanston, Ill. -- New York University School of Medicine, New York, N.Y. For more information about cancer, visit the NCI Web site at http://www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The National Institutes of Health (NIH) -- "The Nation's Medical Research Agency" -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov. ## This NIH News Release is available online at: http://www.nih.gov/news/pr/sep2005/nci-29.htm. To subscribe (or unsubscribe) from this list, go to http://list.nih.gov/cgi-bin/wa?SUBED1=nihpress&A=1.
